We have diligently pursued this project for many years to reach the Phase 2 trial stage. The latest data is from 10 patients, with the next readout scheduled for January. Our share register is as follows:
Institutions: 86.6%
Private Companies: 4.93%
Individual Insiders: 3.64%
General Public: 4.8%
For additional context, please refer to the following relevant links from a company operating in the same field.
https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-finance-and-investment-news/asceneuron-secures-100m-funding-to-advance-therapeutics-in-neurodegenerative-diseases/
https://asceneuron.com/
Value of company post Positive phase 2 trial results, page-2
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $130.5K | 26.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 106 | 98813145 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13634538 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |